Publications

June–July 2019
Article

A Methodology for Operationalizing Enterprise IT Architecture and Evaluating Its Modifiability

By: Robert Lagerström, Alan MacCormack, David Dreyfus and Carliss Y. Baldwin

Recent contributions to information systems theory suggest that the primary role of a firm’s information technology (IT) architecture is to facilitate, and therefore ensure the continued alignment of a firm’s IT investments with a constantly changing business... View Details

Keywords: Enterprise Architecture; Modularity; Information Systems; Modifiability; Design Structure Matrix

Read Now

Paul Gompers, Professor of Business Administration at the Harvard Business School, specializes in research on financial issues related to start-up, high growth, and newly public companies. Professor Gompers has an appointment in both the View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

October 2022
Case

Cost Plus Drugs

By: Alexander MacKay and James Barnett

In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies.... View Details

Keywords: Business Ventures; Decision Making; Entrepreneurship; Ethics; Health; Markets; Social Enterprise; Society; Strategy; Health Care and Treatment; Business Divisions; Factories, Labs, and Plants; Pharmaceutical Industry; Pharmaceutical Industry; United States; Texas

2010
Working Paper

Accelerating Energy Innovation: Insights from Multiple Sectors

By: Rebecca Henderson and Richard G. Newell

A combination of concerns about climate change and energy security has recently led to significant increases in public funding for energy R&D. Some commentators are suggesting that these increases need to be sustained, and are advocating for increases of as much as... View Details

Keywords: Innovation and Management; Technological Innovation; Knowledge Use and Leverage; Research and Development; Pollutants; Climate Change; Energy Industry

Read Now

Career Coach

Roshan Tathed

note to Roshan Employment Experience: Duolingo (Internship), Amazon (PM Tech for Amazon Fresh), Strategy& (Strategy consulting); Indian Pharmaceutical Alliance (Project Management); The Walt Disney Company (Internship) View Details

March 2023 (Revised June 2025)
Case

Close Concerns: Diabetes Research and Advocacy

By: Regina E. Herzlinger and Brian L. Walker

Diagnosed with diabetes at the age of 18, Kelly Close understood the importance of balancing consistency and iteration. This principle had also informed her professional work, which started with a rapid promotion from financial analyst at Goldman Sachs to an analyst... View Details

Keywords: Diabetes; Health; Health Care; Health Care And Treatment; Health Care Outcomes; Health Care Industry; Knowledge Dissemination; Outcome or Result; Equality and Inequality; Business Model; Entrepreneurship

16 Jan 2018
First Look

First Look at New Research and Ideas, January 16, 2018

January–February 2018 Harvard Business Review More Than a Paycheck: How to Create Good Blue-Collar Jobs in the Knowledge Economy By: Campbell, Dennis, John Case, and Bill Fotsch Abstract—Fifty years ago a good blue-collar job was with a large manufacturer such as View Details

Keywords: Sean Silverthorne

Web

Faculty & Advisors | MBA

partner for some of the most impactful and fastest growth companies of their generation including: 10x Genomics (Nasdaq: TXG), Amerigroup (Nasdaq: ANTM), and Jazz Pharmaceuticals (Nasdaq: JAZZ). Jim’s first... View Details

Gary P. Pisano

Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

Karim R. Lakhani

Karim R. Lakhani is the Dorothy & Michael Hintze Professor of Business Administration at the Harvard Business School. He specializes in technology management, innovation, digital transformation and artificial... View Details

Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

02 Feb 2021
Blog Post

Finding My Focus in Health care Amidst a Global Pandemic

decade, legislators have passed countless health care policies that impact how hospitals, insurance companies and pharmaceutical manufacturers deliver services to patients. Even more, the ongoing SARS-CoV-2 pandemic has uncovered major... View Details

07 Jun 2019
Book

Are You a Digital Manager?

purpose; managers need to answer not just what the team should or could be doing, but also why doing so matters. All of us, particularly the younger generations in the workforce, want to be in organizations where we can make a difference.... View Details

Keywords: by Martha Lagace

Research Summary

Putting Patients First: Marketing Strategies for Treating HIV in Developing Nations

It is more than mere coincidence that the highest rates of HIV occur in the world’s poorest countries. Of the over 40 million people currently living with HIV, 95 percent are in the developing world. The first half of this paper explores the economics of HIV and... View Details

2023
Working Paper

Market Exclusivity and Innovation: Evidence From Antibiotics

By: Edward Kong and Olivia Zhao

The US incentivizes drug innovation via patents as well as market exclusivity periods awarded by the US Food and Drug Administration. We estimate the causal effects of extending market exclusivity for an important drug class: antibiotics. Using a... View Details

Keywords: Health Testing and Trials; Innovation and Invention; Motivation and Incentives; Government Administration; Government Legislation; Pharmaceutical Industry; United States

SSRN

March 1993
Supplement

Burroughs Wellcome and AZT (C)

By: Willis M. Emmons III

Describes key developments relating to Burroughs Wellcome, AZT and other AIDS drugs, and the AIDS issue in general from late 1989 through 1992. Includes excerpts from Wellcome PLC's financial statements and updated statistics on AIDS in the United States. View Details

Keywords: Health Pandemics; Multinational Firms and Management; Financial Statements; Pharmaceutical Industry; United States

March 2002 (Revised May 2002)
Case

Genzyme: Engineering the Market for Orphan Drugs

Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details

Keywords: Business Model; Information Technology; Market Entry and Exit; Pharmaceutical Industry; Pharmaceutical Industry